Across TCGA pan-cancer cohorts, PTRHD1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PTRHD1’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where PTRHD1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PTRHD1 is over-expressed in tumor, although a few such as PDAC and CCRCC show the opposite, repressed pattern.

PDAC, CCRCC, and LSCC are the cancer types where PTRHD1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTRHD1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Male	All	−0.491	<.001	9	view →
CCRCC	Male	All	−0.200	<.001	9	view →
LSCC	Male	III,IV	−0.423	<.001	8	view →
HNSC	Male	All	−0.345	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PTRHD1 RNA expression & survival · all PTRHD1 data types